Pharmaceuticals, Biotechnology and Life Sciences
Glenmark Pharmaceuticals has been granted final approval by the FDA for Clindamycin and Benzoyl Peroxide Gel, 1%|5%, a generic version of BenzaClin Gel, 1%|5%, of Valeant Bermuda.
Alvotech has enrolled the first patient to test its Humira biosimilar candidate in Alvopad PS, in a Phase III clinical study (ALVOPAD PS), for adult patients with moderate to severe chronic plaque psoriasis.
Eli Lilly’s Phase 3 RELAY study of Cyramza showed improvement in the time patients lived without their cancer growing or spreading after starting treatment, the company said Tuesday.
InventisBio said Tuesday it raised $70 million in a Series C financing in January 2019, to accelerate the development of its clinical candidates into phase 2 trials and help us developfirst-in-class drug candidates into clinical stage.
Pfizer got approval for Trazimera n USA for the treatment of human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 adenocarcinoma.
Roche said Monday it got accelerated approval to Tecentriq plus chemotherapy for the treatment of adults with unresectable triple-negative breast cancer (TNBC) in people whose tumours express PD-L1, as determined by an FDA-approved test.
Sedana Medical phase III study of candidate drug IsoConDa (isoflurane) for inhalation sedation in intensive care in Europe, shows smaller variations in efficacy than anticipated and the study will therefore only need to cover a total of 300 patients instead of initially estimated 550 patients.
Syndax Pharmaceutical expects the coming months to be a very exciting, milestone-rich, said Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, in a press release Thursday, reporting financial results, fourth quarter ended December 31, 2018.
Dutch Pharming Group N.V. was profitable at the net level in every quarter and for the year as a whole, with the total net profit for the year ended at €25.0 million, representing a net margin of 19% and well ahead of analysts’ forecasts.
Forendo Pharma has completed Phase 1a study of FOR-6219, an HSD17B1 inhibitor for the treatment of endometriosis, with single and multiple ascending oral doses of FOR-6219 in 36 healthy postmenopausal women.